Vivos Therapeutics, Inc. Research and Development Expense
Vivos Therapeutics, Inc. (VVOS) reported Research and Development Expense of $100.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-15.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-04-15
- Vivos Therapeutics, Inc. research and development expense for the quarter ending 2024-03-31 was $100.00K, a 0.00% change year-over-year.
- Vivos Therapeutics, Inc. research and development expense for the quarter ending 2023-12-31 was -$100.00K.
- Vivos Therapeutics, Inc. research and development expense for the quarter ending 2023-09-30 was $100.00K, a 0.00% change year-over-year.
- Vivos Therapeutics, Inc. research and development expense for the quarter ending 2023-06-30 was $100.00K, a 0.00% change year-over-year.
- Vivos Therapeutics, Inc. research and development expense for fiscal 2025 was $100.00K, a 0.00% change from fiscal 2024.
- Vivos Therapeutics, Inc. research and development expense for fiscal 2024 was $100.00K, a 0.00% change from fiscal 2023.
- Vivos Therapeutics, Inc. research and development expense for fiscal 2023 was $100.00K, a 50.00% decline from fiscal 2022.
- Vivos Therapeutics, Inc. research and development expense for fiscal 2022 was $200.00K, a 0.00% change from fiscal 2021.
| Period end | Research and Development Expense | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | $100.00K 10-K · filed 2026-04-15 | ||||||
| 2024-12-31 | $100.00K 10-K · filed 2026-04-15 | ||||||
| 2024-03-31 | $100.00K 10-Q · filed 2024-05-14 | $0.00 derived: sum of 2 quarters · filed 2025-03-31 | $100.00K derived: sum of 3 quarters · filed 2025-03-31 | $200.00K derived: sum of 4 quarters · filed 2025-03-31 | |||
| 2023-12-31 | -$100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $0.00 derived: sum of 2 quarters · filed 2025-03-31 | $100.00K derived: sum of 3 quarters · filed 2025-03-31 | $100.00K 10-K · filed 2025-03-31 | |||
| 2023-09-30 | $100.00K 10-Q · filed 2023-11-14 | $200.00K derived: sum of 2 quarters · filed 2023-11-14 | $200.00K 10-Q · filed 2023-11-14 | $300.00K derived: sum of 4 quarters · filed 2024-07-30 | |||
| 2023-06-30 | $100.00K 10-Q · filed 2023-08-16 | $100.00K 10-Q · filed 2023-08-16 | $200.00K derived: sum of 3 quarters · filed 2024-07-30 | $300.00K derived: sum of 4 quarters · filed 2024-07-30 | |||
| 2023-03-31 | $100.00K 10-Q · filed 2024-05-14 | $100.00K derived: sum of 2 quarters · filed 2024-07-30 | $200.00K derived: sum of 3 quarters · filed 2024-07-30 | $300.00K derived: sum of 4 quarters · filed 2024-07-30 | |||
| 2023-02-28 | $100.00K 10-K · filed 2025-03-31 | ||||||
| 2022-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-07-30 | $100.00K derived: sum of 2 quarters · filed 2024-07-30 | $200.00K derived: sum of 3 quarters · filed 2024-07-30 | $200.00K 10-K/A · filed 2024-07-30 | |||
| 2022-09-30 | $100.00K 10-Q · filed 2023-11-14 | $200.00K derived: sum of 2 quarters · filed 2023-11-14 | $200.00K 10-Q · filed 2023-11-14 | $400.00K derived: sum of 4 quarters · filed 2023-11-14 | |||
| 2022-06-30 | $100.00K 10-Q · filed 2023-08-16 | $200.00K 10-Q · filed 2023-08-16 | $300.00K derived: sum of 3 quarters · filed 2023-08-16 | $400.00K derived: sum of 4 quarters · filed 2023-08-16 | |||
| 2022-03-31 | $100.00K 10-Q · filed 2023-06-08 | $200.00K derived: sum of 2 quarters · filed 2023-06-08 | $300.00K derived: sum of 3 quarters · filed 2023-06-08 | $400.00K derived: sum of 4 quarters · filed 2023-06-08 | |||
| 2021-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $200.00K derived: sum of 2 quarters · filed 2023-03-30 | $300.00K derived: sum of 3 quarters · filed 2023-03-30 | $200.00K 10-K · filed 2023-03-30 | |||
| 2021-09-30 | $100.00K 10-Q · filed 2022-12-20 | $200.00K derived: sum of 2 quarters · filed 2022-12-20 | $100.00K 10-Q · filed 2022-12-20 | ||||
| 2021-06-30 | $100.00K 10-Q · filed 2022-12-20 | $0.00 10-Q · filed 2021-08-12 | $100.00K 10-Q · filed 2022-12-20 | $0.00 10-Q · filed 2021-08-12 | |||
| 2021-03-31 | $100.00K 10-Q/A · filed 2022-11-25 | ||||||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |
| Catheter Precision, Inc. (VTAK) | United States | $0.002B | -0.23 |
| Tenon Medical, Inc. (TNON) | United States | $0.002B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Profusa, Inc. (PFSA) | United States | $0.002B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B |